Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H19BrN2 |
Molecular Weight | 319.239 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC(C1=CC=C(Br)C=C1)C2=NC=CC=C2
InChI
InChIKey=ZDIGNSYAACHWNL-UHFFFAOYSA-N
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e241d83e-996c-494d-b3fe-97f1ef4809edCurator's Comment: description was created based on several sources, including
https://www.drugs.com/mtm/brompheniramine.html
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e241d83e-996c-494d-b3fe-97f1ef4809ed
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/mtm/brompheniramine.html
Brompheniramine is an antihistaminergic medication of the propylamine class. It is a first-generation antihistamine, which is used for the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing. In allergic reactions, an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Brompheniramine is a histamine H1 antagonist of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Brompheniramine is metabolised by cytochrome P450s. The halogenated alkylamine antihistamines all exhibit optic isomerism and brompheniramine products contain racemic brompheniramine maleate whereas dexbrompheniramine (Drixoral) is the dextrorotary (right-handed) stereoisomer.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10212017 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | BROMFED-DM (BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE) Approved UseFor relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. Launch Date4.86950404E11 |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6128358/ |
0.13 mg/kg single, oral dose: 0.13 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
284 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6128358/ |
0.13 mg/kg single, oral dose: 0.13 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6128358/ |
0.13 mg/kg single, oral dose: 0.13 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. | 1975 Sep 4 |
|
Phenylpropanolamine and mental disturbances. | 1979 Dec 22-29 |
|
pH-independent large-volume sample stacking of positive or negative analytes in capillary electrophoresis. | 2001 Jan |
|
Toxicity of over-the-counter cough and cold medications. | 2001 Sep |
|
Update on medical treatment of ejaculatory disorders. | 2002 Dec |
|
Involvement of calmodulin inhibition in analgesia induced with low doses of intrathecal trifluoperazine. | 2002 Feb |
|
First do no harm: managing antihistamine impairment in patients with allergic rhinitis. | 2003 May |
|
Antihistamines in the treatment of dermatitis. | 2003 Nov-Dec |
|
Retentivity and enantioselectivity of uniformly sized molecularly imprinted polymers for d-chlorpheniramine and -brompheniramine in hydro-organic mobile phases. | 2004 May 5 |
|
Laboratory exposures to staphylococcal enterotoxin B. | 2004 Sep |
|
Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. | 2005 Oct |
|
Nimesulide-induced fixed drug eruption. | 2005 Sep-Oct |
|
The combined luminol/isoluminol chemiluminescence method for differentiating between extracellular and intracellular oxidant production by neutrophils. | 2006 |
|
Role of chemical structure in stereoselective recognition of beta-blockers and H1-antihistamines by human serum transferrin in capillary zone electrophoresis. | 2006 Apr |
|
Antiradical effects of antihistamines in human blood. Structure-activity relationship. | 2006 Apr |
|
Analysis of pharmaceutical preparations containing antihistamine drugs by micellar liquid chromatography. | 2006 Feb 13 |
|
Optimization by factorial design of a capillary zone electrophoresis method for the simultaneous separation of antihistamines. | 2006 May 1 |
|
Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. | 2007 Apr 20 |
|
First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. | 2007 May |
|
The effect of achiral calixarenes on chiral separation of propranolol-HCl and brompheniramine maleate in capillary electrophoresis using cyclodextrin as chiral selector. | 2008 Apr |
|
Cough and cold medication use by US children, 1999-2006: results from the slone survey. | 2008 Aug |
|
Drug-liposome distribution phenomena studied by capillary electrophoresis-frontal analysis. | 2008 Aug |
|
Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. | 2008 Dec |
|
Indirect fluorescent determination of selected nitro-aromatic and pharmaceutical compounds via UV-photolysis of 2-phenylbenzimidazole-5-sulfonate. | 2008 Feb 15 |
|
Possibilities of column coupling electrophoresis provided with a fiber-based diode array detection in enantioselective analysis of drugs in pharmaceutical and clinical samples. | 2008 Jan 25 |
|
Surface degradation of composite resins by acidic medicines and pH-cycling. | 2008 Jul-Aug |
|
Comparison of chiral separation of basic drugs in capillary electrophoresis and liquid chromatography using neutral and negatively charged cyclodextrins. | 2009 Jul 10 |
|
Enantioseparation of a novel "click" chemistry derived native beta-cyclodextrin chiral stationary phase for high-performance liquid chromatography. | 2009 Mar 20 |
|
Halogenation effects of pheniramines on the complexation with beta-cyclodextrin. | 2009 Oct 15 |
|
Commonly prescribed medications and potential false-positive urine drug screens. | 2010 Aug 15 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to under 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (½ teaspoonful) every 4 hours. Infants 6 months to under 2 years of age:
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9578932
The anticholinergic properties of brompheniramine was assessed in an in vitro model of human nasal mucosal glandular secretion. The effective dose reducing methacholine-induced secretion (ED50) was determined. ED50 was 4.10 microM for rompheniramine.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR06AB01
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
||
|
LIVERTOX |
124
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
||
|
WHO-VATC |
QR06AB51
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
||
|
WHO-ATC |
R06AB01
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
||
|
WHO-ATC |
R06AB51
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D001977
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
86-22-6
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
BROMPHENIRAMINE
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
6834
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
C61655
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
408
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
CHEMBL811
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
3017
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
DB00835
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
32188-07-1
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
SUPERSEDED | |||
|
201-657-8
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
H57G17P2FN
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
H57G17P2FN
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
DTXSID5022691
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
156428-33-0
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
SUPERSEDED | |||
|
7133
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
SUB05924MIG
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
100000092553
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
m2723
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | Merck Index | ||
|
1767
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | RxNorm | ||
|
770
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
3183
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY | |||
|
Brompheniramine
Created by
admin on Sat Dec 16 16:45:06 UTC 2023 , Edited by admin on Sat Dec 16 16:45:06 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)